Infraestructura de Medicina de Precisión asociada a la Ciencia y la Tecnología
Metabolic dysfunction-associated fatty liver disease (MAFLD) is the leading cause of chronic liver disease in Western countries. The project aims to identify non-invasive metabolite signatures to stratify patients and personalize disease management. Through the integration of multi-omics data and collaboration with the IMPaCT platform, these biomarkers will be validated and a clinical scoring system optimized by artificial intelligence will be developed.
Scientific impact:
The project aims to bring a new understanding of the biomarkers and metabolic pathways involved in the progression of MAFLD. The identification of metabokines and their relationship with metabolic dysfunction will allow the development of new targeted therapies. The use of advanced omics tools and their integration with artificial intelligence will offer innovative results in the characterization of MAFLD subtypes, significantly improving diagnosis and treatment.
Impact on the NHS and patients:
The implementation of a risk score based on non-invasive biomarkers will improve the stratification and personalized management of patients with MAFLD in the NHS. This will allow early detection of patients at higher risk of complications, optimizing healthcare resources and reducing the need for invasive liver biopsies. In addition, personalized therapies derived from the study of metabokines will have a direct impact on reducing the morbidity and mortality associated with this disease.